Vutrisiran benefit holds in 40% of ATTR-CM patients on tafamidis

For cardiologists and health system leaders, the HELIOS-B subgroup answers a practical clinical question: can vutrisiran help the 40% of ATTR-CM patients already on tafamidis? Data presented at ESC 2026 suggest consistent benefit regardless of baseline stabilizer use, which could simplify add-on and switching decisions across cardiology practices.

Alnylam Pharmaceuticals used the European Society of Cardiology Congress 2026 to release a prespecified subgroup analysis from its pivotal HELIOS-B Phase 3 trial, arguing that the RNAi therapeutic vutrisiran delivers consistent cardiovascular benefit in transthyretin amyloid cardiomyopathy regardless of whether patients entered the study already taking tafamidis, the most widely used stabilizer in the disease. According to the company announcement distributed on August 30, 2026, among 654 randomized and treated patients, 259 patients, or 40 percent, were receiving tafamidis at baseline. The treatment effect for vutrisiran on the primary composite endpoint of all-cause mortality and recurrent cardiovascular events through 33 to 36 months was consistent irrespective of baseline tafamidis use. The data were presented as a late-breaking oral and simultaneously published in the Journal of the American College of Cardiology. This is a press-release-driven disclosure, so the company's framing should be treated as a claim pending full independent review, though the simultaneous JACC publication does add scientific weight.

“

For cardiologists and health system leaders, the HELIOS-B subgroup answers a practical clinical question: can vutrisiran help the 40% of ATTR-CM patients already on tafamidis?

The clinical significance of the tafamidis subgroup is substantial. ATTR-CM is a progressive and often fatal cardiomyopathy caused by misfolded transthyretin protein accumulating in the heart. Tafamidis acts as a stabilizer, binding TTR to slow but not stop misfolding. Vutrisiran, by contrast, is an RNAi therapeutic that silences TTR messenger RNA in the liver, reducing production of the pathogenic protein upstream. Clinicians have faced a practical question: for patients already on tafamidis, does adding or switching to an RNAi silencer produce meaningful incremental benefit? The HELIOS-B subgroup offers an answer that could simplify treatment algorithms and expand the addressable population for Alnylam. If the effect holds across the stabilizer-treated subgroup, physicians may have more confidence in switching or adding vutrisiran rather than waiting for disease progression on tafamidis alone.

The competitive backdrop makes these data strategically important. Pfizer's tafamidis franchise has dominated ATTR-CM for years, and newer entrants such as BridgeBio's acoramidis and other TTR-targeting programs are competing for a growing but increasingly crowded market. Alnylam's message at ESC 2026 is that RNAi-mediated silencing is a foundational mechanism, not a niche alternative. By demonstrating consistency in a hard-to-treat subgroup, Alnylam is directly addressing one of the most common objections to combination or sequencing strategies in ATTR-CM. The primary composite endpoint of all-cause mortality and recurrent cardiovascular events through 33 to 36 months is a rigorous measure, and consistency across baseline tafamidis use matters both clinically and commercially. Payers and guideline committees may view these data as evidence that vutrisiran belongs earlier in the treatment pathway, potentially before stabilizers.